Cantor Fitzgerald Reiterates Overweight on ORIC Pharmaceuticals
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Prakhar Agrawal has reiterated an Overweight rating on ORIC Pharmaceuticals (NASDAQ:ORIC).
May 28, 2024 | 1:13 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald analyst Prakhar Agrawal has reiterated an Overweight rating on ORIC Pharmaceuticals, indicating a positive outlook for the stock.
The reiteration of an Overweight rating by a reputable analyst suggests confidence in ORIC Pharmaceuticals' future performance, likely leading to a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100